. 2009 Aug 17;11(4):R124. doi: 10.1186/ar2790

Table 6.

Mean change in PRO measures from week 24 to each follow-up visit

PRO measure	Time point from baseline of the ATLAS study

	Week 36	Week 52	Week 76	Week 104	Week 128	Week 156
BASDAI
n	278	274	270	262	242	236
Mean change ± SD	-0.2 ± 1.41	-0.4 ± 1.59	-0.5 ± 1.65	-0.6 ± 1.87	-0.6 ± 1.80	-0.5 ± 2.88
P-value^a	0.004	< 0.001	< 0.001	< 0.001	< 0.001	0.009
BASFI
n	278	274	270	261	242	236
Mean change ± SD	-1.1 ± 10.68	-3.1 ± 13.07	-4.4 ± 14.22	-5.0 ± 15.90	-4.6 ± 15.87	-5.5 ± 14.27
P-value^a	0.100	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
SF-36 PCS
n	^b	268	267	259	232	231
Mean change ± SD	^b	1.8 ± 6.71	2.2 ± 7.35	2.4 ± 7.60	2.5 ± 8.54	2.6 ± 7.94
P-value^a	^b	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
SF-36 MCS
n	^b	268	267	259	232	231
Mean change ± SD	^b	0.7 (7.55)	0.1 (7.50)	0.6 (7.37)	-1.2 (8.60)	0.2 (8.29)
P-value^a	^b	0.150	0.892	0.176	0.033	0.718
ASQOL
n	^b	274	270	263	242	236
Mean change ± SD	^b	-0.5 (2.73)	-0.7 (2.78)	-1.0 (3.01)	-0.8 (3.43)	-1.0 (3.07)
P-value^a	^b	0.002	< 0.001	< 0.001	< 0.001	< 0.001

^aP-values based on paired Student t-test.

^bMeasure not assessed at this time point.

ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; MCS = Mental Component Summary; PCS = Physical Component Summary; PRO = patient-reported outcome; SF-36 = Short Form-36 Health Survey.